To evaluate the positive predictive value (PPV) of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) assessment method in patients with a single suspicious finding on prostate multiparametric magnetic resonance imaging (mpMRI).
A total of 176 patients underwent MRI/ultrasound fusion-targeted prostate biopsy after the detection of a single suspicious finding on mpMRI. The PPV for cancer detection was determined based on PI-RADS v2 assessment score and location.
Fusion biopsy detected prostate cancer in 60.2% of patients. Of these patients, 69.8% had Gleason score (GS) ≥7 prostate cancer. Targeted biopsy detected 90.5% of all GS≥7 prostate cancer. The PPV for GS≥7 detection of PI-RADS v2 category 5 (P5) and category 4 (P4) lesions was 70.2% and 37.7%, respectively. This increased to 88% and 38.5% for P5 and P4 lesions in the peripheral zone (PZ), respectively. Targeted biopsy did not miss GS≥7 disease compared with systematic biopsy in P5 lesions in the PZ and transition zone.
The PPV of PI-RADS v2 for prostate cancer in patients with a single lesion on mpMRI is dependent on PI-RADS assessment category and location. The highest PPV was for a P5 lesion in the PZ.
Urologic oncology. 2017 May 10 [Epub ahead of print]
Jamil S Syed, Kevin A Nguyen, Cayce B Nawaf, Ansh M Bhagat, Steffen Huber, Angelique Levi, Peter Humphrey, Jeffrey C Weinreb, Peter G Schulam, Preston C Sprenkle
Department of Urology, Yale School of Medicine, New Haven, CT., Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT., Department of Pathology, Yale School of Medicine, New Haven, CT., Department of Urology, Yale School of Medicine, New Haven, CT. Electronic address: .